Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6385488 | VYTERIS | Circuits for increasing the reliability of an iontophoretic system |
Sep, 2013
(10 years ago) | |
US6862473 | VYTERIS | Iontophoretic drug delivery device and reservoir and method of making same |
Sep, 2013
(10 years ago) | |
US6377847 | VYTERIS | Iontophoretic drug delivery device and reservoir and method of making same |
Sep, 2013
(10 years ago) | |
US5873850 | VYTERIS | Locking and disfiguring mechanism for an iontophoretic system |
Sep, 2013
(10 years ago) | |
US5246418 | VYTERIS | Iontophresis system having features for reducing skin irritation |
Sep, 2013
(10 years ago) | |
US6629968 | VYTERIS | Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system incorporating the reservoir-electrode |
Jun, 2020
(3 years ago) | |
US6635045 | VYTERIS | Electrodes and method for manufacturing electrodes for electrically assisted drug delivery |
Jun, 2021
(2 years ago) |
Lidosite Topical System Kit is owned by Vyteris.
Lidosite Topical System Kit contains Epinephrine; Lidocaine Hydrochloride.
Lidosite Topical System Kit has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Lidosite Topical System Kit are:
Lidosite Topical System Kit was authorised for market use on 06 May, 2004.
Lidosite Topical System Kit is available in patch;iontophoresis, topical dosage forms.
The generics of Lidosite Topical System Kit are possible to be released after 29 June, 2021.
Drugs and Companies using EPINEPHRINE; LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 May, 2004
Treatment: NA
Dosage: PATCH;IONTOPHORESIS, TOPICAL